FIRST AND ONLY
*Estimate is based on IQVIA US sales and prescription data from April 2017 to May 2019.
A Phase 2, open-label, single-arm, multicenter trial
†According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as measured by blinded independent central review committee.
‡Assessed by independent central review committee.
§Absence of significant clinical deterioration was defined as no new or worsening symptoms, no change in performance status for ≥ 2 weeks, and no need for salvage therapy.
Patient characteristics in the 2nd-line+ cohort
In a Phase 2, open-label, single-arm, multicenter study of 88 patients with mMCC whose disease progressed on or after chemotherapy for distant metastatic disease
Complete responses were also observed
||Response criteria were defined according to RECIST v1.1.
CI, confidence interval.
Responses were observed regardless of PD-L1 tumor expression or presence of Merkel cell polyomavirus (MCPyV)
35% (n=31/88) of study patients had received 2 or more lines of previous therapy
Among patients with confirmed response (n=29)
86% (n=25/29) of responses lasted for atleast 6 months (range: 2.8 to 23.3+ months)
45% (n=13/29) of responses lasted for atleast 1 year (range: 2.8 to 23.3+ months)
The median duration of response had not yet been reached at the time of analysis, with a minimum follow-up of 12 months.
29 of 88 patients had a complete or partial response2
In the JAVELIN Merkel 200 study2:
In a subsequent analysis of the JAVELIN Merkel 200 study, with a minimum follow-up of 2 years (data cut-off on September 26, 2017), which did not account for censoring
¶These data on durations of response are based on different data with a minimum of 2 years of follow-up in all patients (EMR 100070-003 Part A; cutoff date: September 26, 2017). The relative frequencies presented do not account for censoring.
aFatigue is a composite term that includes fatigue and asthenia.
bInfusion-related reaction is a composite term that includes drug hypersensitivity, hypersensitivity, chills, pyrexia, back pain, and hypotension.
cPeripheral edema is a composite term that includes peripheral edema and peripheral swelling.
dMusculoskeletal pain is a composite term that includes back pain, myalgia, neck pain, and pain in extremity.
eAbdominal pain is a composite term that includes abdominal pain and abdominal pain upper.
fRash is a composite term that includes rash maculopapular, erythema, and dermatitis bullous.
gPruritus is a composite term that includes pruritis and pruritis generalized.
hDyspnea is a composite term that includes dyspnea and dyspnea exertional.
*Excluding temporary dose interruption for infusion-related reactions where infusion was restarted the same day.
The median duration of exposure to BAVENCIO was 4 months (range: 2 weeks to 21 months). 40% of patients received BAVENCIO for more than 6 months and 14% were treated for more than one year
No new safety signals were observed in a 2-year follow-up3
RECOMMENDED by the National Comprehensive Cancer Network® (NCCN®) as an option for patients with disseminated Merkel cell carcinoma (category 2A)6
The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Poor historical survival in metastatic MCC8
MCC is rare, but the incidence is growing
References: 1. U.S. National Library of Medicine. DailyMed: Advanced Search. Indication And Usage Section (34067-9). Accessed October 1, 2019. 2. Data on file. Rockland, Mass: EMD Serono, Inc. 3. Nghiem P, Bhatia S, Brohl AS, et al. Two-year efficacy and safety update from JAVELIN Merkel 200 part A: a registrational study of avelumab in metastatic cell carcinoma progressed on chemotherapy. Presented at: 2018 American Society of Clinical Oncology Annual Meeting; June 1-5, 2018; Chicago, IL. Abstract 9507. 4. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374-1385. 5. ClinicalTrials.gov. Accessed October 1, 2019. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Merkel Cell Carcinoma. Version 2.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed October 1, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. 7. Chapter 30, Merkel cell carcinoma. In: Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010:315-323. 8. Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63(5):751-761. 9. Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78:457-463. 10. Poulsen M, Rischin D, Walpole E, et at; Trans-Tasman Radiation Oncology Group. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study-TROG 96:07. J Clin Oncol. 2003;21(23):4371-4376. 11. Cowey CL, Mahnke L, Espirito J, et al. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699-1710.